1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Clinical factors and outcomes in infants with invisible posterior crossroads and those without
Visible (n = 94)Invisible(n = 13)P Value
Gestational age at birth (week) (SD)27.8 (2.0)26.6 (1.4).03
Gestational age at MRI (week) (SD)40.2 (1.2)40.9 (2.2).29
Birthweight (gram) (SD)987 (215)885 (227).13
Male (No.) (%)52 (55.3)7 (53.8).92
Small for gestational age (No.) (%)12 (12.8)0.17
Singleton (No.) (%)57 (60.6)10 (76.9).26
Antenatal corticosteroids (No.) (%)84 (89.4)11 (84.6).61
Postnatal corticosteroids (No.) (%)4 (4.3)4 (30.8).001
Postnatal sepsis (No.) (%)39 (41.5)8 (61.5).17
Necrotizing enterocolitis (No.) (%)5 (5.3)0.39
Bronchopulmonary dysplasia at 36 weeks (No.) (%)29 (30.9)5 (38.5).58
Inotropic support (No.) (%)30 (31.9)6 (46.2).31
Operated patent ductus arteriosus (No.) (%)5 (5.3)2 (15.4).17
MDI scores (SD)87.1 (18.9)75.9 (18.3).047
Significant delay in MDI (No.) (%)12 (13.0)5 (38.5).02
PDI scores (SD)88.9 (16.1)88.1 (11.1).86
Significant delay in PDI (No.) (%)11 (12.0)2 (15.4).73
Cerebral palsy (No.) (%)2 (2.1)0.60
  • 

    Note:—MRI = MR imaging.